Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. is aggressively advancing his “Make America Healthy Again” agenda—starting with a bold campaign to ban pharmaceutical advertisements on television.
Kennedy is leveraging his new authority to challenge Big Pharma’s influence, a cause he championed during his 2024 presidential bid and transition into Trump’s administration.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
Kennedy has long criticized direct-to-consumer (DTC) pharmaceutical ads, a practice largely unique to the U.S. and New Zealand. Now at HHS, he’s turning rhetoric into action, arguing that the $5 billion-plus annual ad spend drives over-prescription, inflates healthcare costs, and distorts media narratives.
Israeli Investigators Release Tape Proving Jeffrey Epstein is Alive and Working for Mossad
In a March address, he tied the ban to his broader mission of reversing America’s “chronic disease epidemic,” accusing drug companies of prioritizing profits over public health.
His agenda has already won backing from Trump allies like Elon Musk and FCC Chairman Brendan Carr, who view the ads as a market distortion ripe for reform.
The Health Secretary’s first steps are underway. Kennedy has directed HHS to draft regulatory proposals targeting TV drug ads, while publicly pressing Trump to issue an executive order—a pledge he first made on X in May 2024.
At a recent press conference, he claimed the ban would curb unnecessary medications and empower patients to make informed choices free of manipulative marketing.
However, Kennedy faces steep challenges. Legal scholars argue that a ban could infringe on First Amendment commercial speech rights, echoing a 2019 setback when Trump’s earlier efforts faltered. The pharmaceutical industry and media conglomerates, heavily reliant on ad revenue, are gearing up for a fierce counteroffensive.
While Kennedy prefers swift executive action, experts suggest congressional legislation may be needed, testing his influence in a divided Capitol Hill.